When PSA Plays Hide and Seek: Why Your Scans Matter More Than You Think

Cancer cells are basically the Ocean's Eleven of your body - constantly running elaborate heists while trying not to trip any alarms. And in prostate cancer, the alarm system everyone relies on is PSA (prostate-specific antigen), that blood marker your doctor checks religiously. But here's the twist M. Night Shyamalan would appreciate: sometimes the cancer is spreading while PSA sits there like a sleeping security guard, completely oblivious.

A new study published in the Journal of Clinical Oncology just dropped some sobering data that oncologists need to hear, and patients definitely need to understand.

The Plot Thickens: Cancer Moves in Silence

Researchers analyzed data from over 2,500 patients across two major clinical trials - ARCHES and PROSPER - looking at men with advanced prostate cancer treated with enzalutamide, a powerful hormone therapy that's become a standard weapon in the oncology arsenal.

What they found reads like a medical thriller. In patients taking enzalutamide, a significant chunk developed radiographic progression (fancy speak for "we can see the cancer spreading on scans") without their PSA levels budging. We're talking about 25% of patients in one trial and 22% in another showing disease progression on imaging while their PSA remained flat or even decreased.

Compare that to the control groups, where only about 4-7% had this "silent progression." That's a massive difference.

Why Is This Happening?

Think of enzalutamide like putting your cancer on a strict diet - it blocks the hormones that prostate cancer cells love to feast on. Most cancer cells either starve or at least stop producing PSA, which makes your blood tests look reassuring.

But some sneaky cancer cells adapt. They figure out how to survive and spread without relying on the usual hormone-driven pathways. These rebels don't produce much PSA, so they fly under the radar of standard blood monitoring. It's like catching criminals who've ditched their cell phones - you can't track what isn't transmitting.

The study also flagged something concerning: liver metastases were more than five times more common in enzalutamide-treated patients whose cancer progressed compared to control groups. Liver involvement in prostate cancer is notoriously aggressive and associated with worse outcomes, suggesting these treatment-resistant cells may be particularly nasty variants.

The Real-World Translation

Here's what this means if you or someone you know is on enzalutamide for advanced prostate cancer: a stable or falling PSA is not a guarantee that everything's fine.

The researchers found that patients whose cancer progressed - whether or not their PSA rose - had significantly worse overall survival compared to those without progression. The PSA-negative progression patients weren't somehow protected by their "good" blood work. Cancer spreading is cancer spreading, regardless of what one biomarker says.

This isn't about inducing panic. Enzalutamide remains an effective treatment that extends lives. But it does mean the monitoring strategy needs updating.

What Should Change?

The study authors recommend periodic imaging surveillance for patients on enzalutamide, regardless of PSA trends. Current guidelines vary, and many oncologists lean heavily on PSA monitoring because it's cheap, easy, and traditionally reliable. This data suggests that approach may miss critical progression in a meaningful percentage of patients.

Advanced imaging techniques like PSMA-PET scans, which can detect prostate cancer spread with remarkable sensitivity, may become increasingly important for this population. It's more expensive and less accessible, but potentially catches what PSA misses.

Other research supports this direction. A 2022 review in European Urology emphasized that androgen receptor-targeted therapies can induce treatment-emergent neuroendocrine differentiation - basically, prostate cancer cells morphing into a different, PSA-negative beast that's harder to track and treat [1]. Another study in The Lancet Oncology found that early detection of oligoprogression (limited spread) through imaging could enable targeted interventions that delay systemic treatment changes [2].

The Bottom Line

Prostate cancer on modern hormone therapy is playing 4D chess while we're sometimes still monitoring with checkers. PSA remains useful, but it's not the whole story - especially for patients on potent androgen receptor inhibitors like enzalutamide.

If you're in this situation, talk to your oncologist about imaging schedules. Ask about the role of periodic scans even when your PSA looks stable. Being proactive about surveillance isn't paranoia - according to this study, it's just good medicine.

The cancer might be trying to pull a fast one, but that doesn't mean we have to let it.

References

1. Armstrong AJ, Azad AA, Iguchi T, et al. Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide. J Clin Oncol. 2025. DOI: 10.1200/JCO-24-02829

2. Beltran H, Hruszkewycz A, Scher HI, et al. The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance. Clin Cancer Res. 2019;25(23):6916-6924. DOI: 10.1158/1078-0432.CCR-19-1423. PMCID: PMC6891125

3. Ost P, Reynders D, Decaestecker K, et al. Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial. J Clin Oncol. 2018;36(5):446-453. DOI: 10.1200/JCO.2017.75.4853. PMCID: PMC6075846

4. Sartor O, de Bono JS. Metastatic Prostate Cancer. N Engl J Med. 2018;378(7):645-657. DOI: 10.1056/NEJMra1701695

Disclaimer: The image accompanying this article is for illustrative purposes only and does not depict actual experimental results, data, or biological mechanisms.